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Introduction: Focal adhesion kinase (FAK) plays a significant 
role in cancer cell survival signaling and is overexpressed in vari-
ous malignancies, including lung cancer. Previous studies sug-
gest that FAK overexpression is an independent factor predicting 
poor prognosis in non–small-cell lung cancer (NSCLC). The aim 
of this study is to confirm these findings specifically in stage I 
NSCLC.
Methods: A retrospective tissue microarray (TMA) analysis of FAK 
protein expression by immunohistochemistry was performed in 157 
surgically resected stage I NSCLC specimen and in the correspond-
ing matched normal lung tissue. The FAK 4.47 monoclonal antibody 
was used for FAK immunostaining. The scoring system of triplicate 
tumor cores included intensity of staining plus extent of staining for 
a composite score that ranged from 0 to 6. The association between 
FAK score and survival was evaluated.
Results: There were 103 stage IA and 54 stage IB patients, with 
mean follow-up of 5.5 years. Normal lung alveoli and interstitial 
tissue had mean FAK score of 0 (median score 0, range 0 to 2). 
Tumor samples had mean FAK score 3.1 (median score 3.5, range 
0–6), with 57% of the samples having FAK score ≥ 3. Continuous 
FAK score was not associated with demographic data, tumor his-
tology, or grade, nor survival in this cohort of stage I NSCLC 
patients.
Conclusions: FAK is expressed in more than 50% of stage I NSCLC lung 
cancer but not in normal lung alveoli and interstitial tissue. FAK expression 
is not associated with survival outcome in this North American cohort.
Key Words: Focal adhesion kinase, Prognosis, Non–small-cell lung 
cancer, Tumor marker
(J Thorac Oncol. 2014;9: 1278–1284)
Lung cancer is the most common cause of death from can-cer worldwide, with an estimated 1.4 million deaths in 
2008.1 The overall 5-year survival rate is less than 20%,2 
reflecting the advanced stage of the lung cancer at diagno-
sis in majority of patients. However, even among pathologic 
stage I lung cancers, outcomes vary according to specific 
tumor node metastasis classification, with 5-year survival 
between 58% and 83% at best.3 A five-gene signature has 
been shown to be an independent predictor of relapse-free 
and overall survival among non–small-cell lung cancer 
(NSCLC) patients.4 However, rapid and widespread adop-
tion of this assay platform is limited. It is thus critical to 
identify biomarkers using easily reproducible assays to 
improve risk-stratification in stage I NSCLC for future adju-
vant studies.
Focal Adhesion Kinase (FAK) is a 125 kDa protein 
tyrosine kinase that is overexpressed in a number of different 
types of solid tumors.5,6 FAK suppresses apoptosis in tumor 
cells and is critical for survival, invasion, and metastasis.7–9 
FAK has been shown to be overexpressed in colon tumors 
compared with normal matched samples by both immuno-
histochemistry (IHC) and reverse-transcriptase polymerase 
chain reaction (RT-PCR).6 Recently, FAK was found to be 
overexpressed in lung tumors, and its higher expression cor-
related with nodal spread and advanced disease stages,10–12 
suggesting its important role in lung cancer progression and 
metastasis. Moreover, activation of FAK, along with proto-
oncogene SRC, Rous sarcoma, promote cell migration, and 
adhesion in liver kinase B1 (LKB1)-deficient KRAS mutant 
lung tumors, a genotype associated with high propensity 
for nodal and distant metastases.13 As SRC is a substrate of 
activated FAK,5 there maybe a potential therapeutic role for 
SRC inhibitors such as dasatinib in FAK-activated NSCLC. 
We thus hypothesized that FAK expression may discriminate 
stage I NSCLC patients who are at high-risk for relapse and 
mortality from lung cancer. FAK expression was thus eval-
uated by IHC in a retrospective cohort of stage I NSCLC 
patients who underwent curative surgical resection.
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PATIENTS AND METHODS
Patients and Tissue Samples
The Roswell Park Cancer Institute Institutional Review 
Board approved this retrospective project in compliance with 
federal, state and local requirements. All clinical and outcome 
patient data were de-identified. Tumor specimens and matched 
normal lung tissue were collected from patients who under-
went surgical resection of lung cancer at Roswell Park Cancer 
Institute, Buffalo, NY.
Patients with small cell or mixed histologies with small 
cell component were excluded from this study. One-hundred 
and fifty seven patients diagnosed with pathologic stage I 
NSCLC between December 1992 and October 2008 who had 
sufficient tissue for this project were included in the analysis. 
Median follow-up duration was 5.1 years (range 0.1–15.5 
years). The American Joint Committee on Cancer staging cri-
teria (Sixth edition) was used for all patients for uniformity of 
pathologic staging.
Tissue Microarrays (TMA)
TMA’s were constructed from formalin-fixed paraffin-
embedded tissues with tumors. TMA’s containing lung tumors 
and matched normal tissues from 161 samples were prepared 
with each tumor and normal core sample in triplicate. Three 
0.6 mm tissue cores from formalin-fixed paraffin-embedded 
donor blocks were precisely arrayed into a new recipient par-
affin block. Each patient had three lung tumor tissue cores on 
a TMA slide.
TABLE 1.  Characteristics of NSCLC Cases Analyzed for Focal Adhesion Kinase (FAK) Staining According to Disease Stage
Stage 1A Stage 1B Overall p Value
Patients N 103 (65.6) 54 (34.4) 157 (100%)
Age at Dx Mean/SE 67.4/1.0 67.9/1.2 67.6/0.7 0.827
Median/min/max 68.0/46.4/85.5 67.2/47.8/85.8 67.3/46.4/85.8
Sex Female 59 (57.3%) 23 (42.6%) 82 (52.2%) 0.080
Male 44 (42.7%) 31 (57.4%) 75 (47.8%)
Race Caucasian 94 (91.3%) 47 (87.0%) 141 (89.8%) 0.074
African American 5 (4.9%) 7 (13.0%) 12 (7.6%)
Other 4 (3.9%) 4 (2.5%)
Smoking Current 36 (35.0%) 15 (27.8%) 51 (32.5%) 0.453
Previous 62 (60.2%) 35 (64.8%) 97 (61.8%)
Never 5 (4.9%) 3 (5.6%) 8 (5.1%)
Othera 1 (1.9%) 1 (0.6%)
Alcohol Current 19 (18.4%) 8 (14.8%) 27 (17.2%) 0.636
Previous 6 (5.8%) 5 (9.3%) 11 (7.0%)
Never 19 (18.4%) 7 (13.0%) 26 (16.6%)
Othera 59 (57.3%) 34 (63.0%) 93 (59.2%)
Histology Adenocarcinoma 55 (53.4%) 25 (46.3%) 80 (51.0%) 0.600
Squamous 38 (36.9%) 20 (37.0%) 58 (36.9%)
NSCLC, NOS 4 (3.9%) 3 (5.6%) 7 (4.5%)
Large cell 6 (5.8%) 6 (11.1%) 12 (7.6%)
Topology Upper lobe 68 (66.0%) 36 (66.7%) 104 (66.2%) 0.843
Lower lobe 29 (28.2%) 16 (29.6%) 45 (28.7%)
Middle lobe 6 (5.8%) 2 (3.7%) 8 (5.1%)
Differentiation Poor 53 (51.4%) 31 (57.4%) 84(53.5%) 0.769
Moderate 42 (40.8%) 19 (35.2%) 61 (38.9%)
Well 8 (7.8%) 4 (7.4%) 12 (7.6%)
Periop chemo Yes 6 (5.8%) 14 (25.9%) 20 (12.7%) <0.001
No 97 (94.2%) 40 (74.1%) 137 (87.3%)
Alive/dead Alive 35 (34.0%) 19 (35.2%) 54 (34.4%) 0.880
Dead 68 (66.0%) 35 (64.8%) 103 (65.6%)
Follow-up (Mo) Mean/SE 5.5/0.3 5.5/0.5 5.5/0.3 0.587
Median/min/max 5.3/0.3/14.8 4.9/0.1/15.5 5.2/0.1/15.5
FAK(normal) Mean/SE 0.0/0.0 0.1/0.0 0.0/0.0 0.456
Median/min/max 0.0/0.0/1.7 0.0/0.0/2.0 0.0/0.0/2.0
Dx, diagnosis; FAK (normal), FAK score in normal lung specimen; FAK (tumor), FAK score in tumor specimen; NOS, not otherwise specified; NSCLC, non–small-cell lung 
cancer; Periop chemo, neoadjuvant and/or adjuvant chemotherapy.
aInformation not reported, not available or not collected.
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Immunohistochemical Staining
The immunohistochemical staining was performed with 
FAK 4.47 antibody (Millipore#05-537). For antigen retrieval, 
slides were heated in the microwave for 10 minutes in citrate 
buffer (pH 6.0), followed by a 15 minute cooling period. 
Endogenous peroxidase was quenched with aqueous 3% H
2
O
2
 
for 10 minutes and washed with 1× phosphate-buffered saline 
using 0.5% Tween 20 solution. Slides were loaded on a DAKO 
autostainer and blocked with serum-free protein block solu-
tion (Dako #X0909) for 5 minutes and then probed with FAK 
primary antibody (Millipore #05-537) for 1 hour, followed 
by the biotinylated goat anti-mouse IgG (Jackson Immuno 
Research Labs, #115-065-062) for 30 minutes, then by the 
Elite ABC Kit (Vectastain, #PK-6200) for 30 minutes, and the 
DAB chromagen (Dako, #K4007) for 5 minutes. The slides 
were counterstained with hematoxylin.
Scoring for FAK
Slides were analyzed by two of the coauthors (L.Y. and 
S.P.), board-certified pathologists in a blinded and independent 
manner. The scoring system of triplicate tumor cores included 
intensity of staining (0, none; 1+, weak; 2+, moderate; 3+, 
strong) plus extent of staining which represented the num-
ber of cores with a positive staining (extent 0, no staining in 
three cores; 1, only one core had a positive staining, mild; 2, 
only two cores had a positive staining, moderate; 3, all three 
cores had the positive staining, diffuse). The composite score 
ranged from 0 to 6, which was equal to the sum of the aver-
age intensity and the extent of staining in the three cores. The 
percentage of stained cells was not used in the scoring as FAK 
staining was diffuse within the tumors. Patients with less than 
two tissue sample cores were excluded from analysis.
Statistical Methods
The associations between continuous FAK scores and clin-
ical factors were assessed using nonparametric Spearman corre-
lation or Kruskal-Wallis tests as appropriate. The univariate and 
multivariate associations of clinicopathological patient data and 
FAK lung tumor staining were performed using ordinary least 
squares regression. For further analysis, patients were dichoto-
mized into two groups: FAK tumor score more than or equal to 
3 (a group with intensity of FAK staining ≥ 1 and extent ≥2) and 
FAK tumor less than 3 (a group with intensity <1 and extent < 2). 
Contingency tables were analyzed by Fisher’s Exact Test.
FIGURE 1.  Immunohistochemical analysis of focal adhesion kinase (FAK) expression in stage I non–small-cell lung cancer tissue 
microarray (TMA) samples. FAK expression was detected by immunohistochemical staining with FAK 4.47 monoclonal anti-
body using TMA samples with triplicate tissue cores per tumor stained. Scale bars shown represent 150 micrometers in length. 
Images taken under ×20 magnification. A, representative images of scoring system that measured intensity (0, none; 1+, weak; 
2+, moderate; and 3+, strong). (B) Representative triplicate core showing extent of staining which represented the number of 
cores with a positive staining (extent 0, no staining in three cores; 1, only one core had a positive staining, mild; 2, only 2 cores 
had a positive staining, moderate; 3, all three cores had the positive staining, diffuse). In this example, the “extent” score is 3. 
The total FAK score including the measured intensity is 6.
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Overall survival was defined as time in months between 
enrollment and death or last follow-up, whichever occurred 
first. Multivariate effects on overall survival were assessed 
using multivariate proportional hazards models. Associations 
between overall survival and stage or FAK expression were 
also described by Kaplan Meier curves and Log-rank tests.
Reproducibility of the scores was assessed using a 
set of validation scores from a second independent patholo-
gist. Agreement between the two sets of continuous scores 
was assessed using the Concordance Correlation Coefficient 
(CCC), which ranges between −1 and +1. Higher values indi-
cate better agreement.14 The CCC adjusts for the probability 
of observing good agreement by chance alone.
p values less than 0.05 were considered statistically sig-
nificant, with no adjustment for multiplicity. All analyses were 
obtained using SAS/STAT software, version 9.4, copyright 
2012 SAS Inc. (Cary, NC).
RESULTS
Clinicopathologic Characteristics
Table 1 summarizes the clinical and pathologic charac-
teristics of patients whose tumor specimen were utilized for 
this study. The median age of all patients was 68 (range 46–86 
years). There were 103 stage IA and 54 stage IB patients. There 
was no difference in terms of gender, age, histology, smoking, or 
alcohol use status between stage IA and stage IB patients. Stage 
IB patients received perioperative (neoadjvuant and/or adjuvant) 
systemic therapy more frequently than stage IA patients (26% 
versus 6%, p < 0.001). The male to female ratio was 0.91 (75 male, 
82 female). Majority (90%) identified themselves as Caucasian. 
Current smokers comprised 33% of the group, whereas former 
smokers represented the majority (62%). Histologic subtype was 
divided into four groups: adenocarcinoma, squamous cell carci-
noma, large cell, or poorly differentiated NSCLC not otherwise 
specified (NOS). One case of adenosquamous carcinoma was 
grouped under the adenocarcinoma category.
FAK Expression
The inter-pathologist agreement on the continuous 
patient-level FAK expression scores revealed a CCC of 0.977 
(95% confidence interval [CI]: 0.970–0.984) indicating low 
interobserver variation. Our results showed that FAK expres-
sion was predominantly diffuse and cytoplasmic in distri-
bution in tumor cells whereas its expression was absent in 
normal lung alveoli and interstitial tissue. Figure 1 shows a 
representative image of the range of FAK staining intensity. 
Most of the normal lung tissue did not express FAK, and the 
mean score was equal to 0 (range 0–2), as demonstrated in 
Figure 2. The mean FAK score in the entire group of lung 
tumors was 3.13 (median 3.5, range 0–6). As expected, there 
was no difference in the FAK score of normal lung tissue 
between pathologic stage IA and stage IB patients.
Univariate comparisons of tumor FAK score as con-
tinuous variable showed no association with any of the clini-
copathologic variables, including overall survival. We then 
dichotomized the lung tumors according to the composite FAK 
score: more than equal to 3 and less than 3 as the maximum 
FAK score found in normal alveoli was 2 which may represent a 
transition zone with biological relevance. Fifty seven percent of 
the tumors had FAK scores more than or equal to 3. The remain-
ing 43% of tumors, in the group with FAK score less than 3, had 
a median score of 1.3. We also performed analysis according to 
a higher FAK score cutoff. Twenty-five percent of tumors had 
FAK scores more than or equal to 5. The median FAK score of 
tumors in the FAK score less than 5 group was 2.7.
FAK Score and Clinicopathologic Features
As aforementioned, univariate comparisons of tumor 
FAK score as continuous variable showed no association 
with any of the clinicopathologic variables. Using the above 
dichotomy in FAK scoring, correlation between FAK expres-
sion and clinicopathologic features was analyzed. As shown 
in Table 2, there was no association between lung tumor FAK 
FIGURE 2.  Focal adhesion kinase (FAK) staining in normal 
lung and lung cancer tissue microarray (TMA). (A) Four 
representative TMA cores with normal and tumor samples are 
shown and marked as N1–4 and T1–4, respectively. As seen in 
the upper row, most of the normal lung tissue did not express 
FAK. In comparison, FAK expression is seen in lung cancer 
cells (but not in surrounding stromal tissue). Scale bar shown 
represents 150 micrometers in length. (B) Representative 
magnified (200×) images derived from N2 and T2 samples in 
(A) of FAK staining in normal and tumor sample.
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score of more than or equal to 3 and less than 3 with age, gen-
der, race, smoking status, pathologic stage, histologic subtype 
nor histologic grade. Statistically significant correlations were 
established between tumor FAK score more than or equal to 5 
with histology (adenocarcinoma type), gender (women), and 
alcohol use (never users).
FAK Score and Survival
We subsequently analyzed the relationship between 
FAK score and survival outcomes. The median survival of 
patients with lung tumor FAK score ≥ 3 was 6.3 years (95% 
CI: 4.6–7.4) whereas those with lung tumor FAK score less 
than 3 was 5.1 years (95% CI: 3.5–6.3). This difference was 
not statistically significant (log-rank p = 0.2). Using a higher 
FAK score of 5 as cutoff also did not reveal any association 
as well with survival. Figure 3 shows the Log-rank over-
all survival curve according to FAK score. In comparison, 
the difference in the median survival between stage IA and 
IB patients was not significant (5.8 years versus 5.7 years, 
p = 0.9). Among other clinicopathologic variables in 
TABLE 2.  Correlation Between Immunohistochemical Focal Adhesion Kinase (FAK) Expression Score and Clinicopathological 
Variables
Overall
FAK  
(tumor) < 3
FAK  
(tumor) ≥ 3 p Value
FAK 
(tumor) <5
FAK  
(tumor) ≥ 5 p Value
Patients N 157 (100%) 68 (43.3) 89 (56.7) 118 (75.2) 39 (24.8)
Age at Dx Mean/SE 67.6/0.7 67.2/1.1 67.9/1.0 0.576  67.4/0.8  68.3/1.5 0.689
Median/min/max 67.3/46.4/85.8 66.2/47.2/85.5 68.5/46.4/85.8 66.9/46.4/85.8 70.7/49.1/84.7
Sex Female 82 (52.2%) 34 (50.0%) 48 (53.9%) 0.625 56 (47.5%) 26 (66.7%) 0.037
Male  75 (47.8%) 34 (50.0%) 31 (46.1%) 62 (52.5%) 13 (33.3%)
Race Caucasian 141 (89.8%) 63 (92.6%) 78 (87.6%) 0.565 108 (91.5%) 33 (84.6%) 0.372
African American 12 (7.6%) 4 (5.9%) 8 (9.0%) 7 (5.9%) 5 (12.8%)
Other 4 (2.5%) 1 (1.5%) 3 (3.4%) 3 (2.5%)  1 (2.6%)
Smoking Current 51 (32.5%) 21 (30.9%) 30 (33.7%) 0.243 36 (30.5%) 15 (38.5%) 0.315
Previous 97 (61.8%) 41 (60.3%) 56 (62.9%) 73 (61.9%) 24 (61.5%)
Never 8 (5.1%) 6 (8.8%) 2 (2.2%) 8 (6.8%)
Othera 1 (0.6%) 1 (1.1%) 1 (0.8%)
Alcohol Current 27 (17.2%) 14 (20.6%) 13 (14.6%) 0.767 20 (16.9%) 7 (17.9%) 0.044
Previous 11 (7.0%) 5 (7.4%) 6 (6.7%) 9 (7.6%) 2 (5.1%)
Never 26 (16.6%) 10 (14.7%) 16 (18.0%) 14 (11.9%) 12 (30.8%)
Othera 93 (59.2%) 39 (57.4%) 54 (60.7%) 75 (63.6%) 18 (46.2%)
Histology Adenocarcinoma 80 (51.0%) 33 (48.5%) 47 (52.8%) 0.747 54 (45.8%) 26 (66.7%) 0.044
Squamous 58 (36.9%) 27 (39.7%) 31 (34.8%) 51 (43.2%) 7 (17.9%)
NSCLC,NOS 7 (4.5%) 2 (2.9%) 5 (5.6%) 5 (4.2%) 2 (5.1%)
Large cell 12 (7.6%) 6 (8.8%) 6 (6.7%) 8 (6.8%) 4 (10.3%)
Topology Upper lobe 104 (66.2%) 47 (69.1%) 57 (64.0%) 0.195 77 (65.3%) 27 (69.2%) 0.889
Lower lobe 45 (28.7%) 20 (29.4%) 25 (28.1%) 35 (29.7%) 10 (25.6%)
Middle lobe 8 (5.1%) 1 (1.5%) 7 (7.9%) 6 (5.1%) 2 (5.1%)
Differentiation  Poor 84 (53.5%) 33 (48.5%) 51 (57.3%) 0.544 61 (51.7%) 23 (59.0%) 0.658
Moderate 61 (38.9%) 29 (42.6%) 32 (36.0%) 47 (39.8%) 14 (35.9%)
Well  12 (7.6%) 6 (8.8%) 6 (6.7%) 10 (8.5%) 2 (5.1%)
Stage(Path) 1A 103 (65.6%) 44 (64.7%) 59 (66.3%) 0.836 77 (65.3%) 26 (66.7%) 0.872
1B 54 (34.4%) 24 (35.3%) 30 (33.7%) 41 (34.7%) 13 (33.3%)
Periop chemo Yes 20 (12.7%) 7 (10.3%) 13 (14.6%) 0.422 14 (11.9%) 6 (15.4%) 0.568
No 137 (87.3%) 61 (89.7%) 76 (85.4%) 104 (88.1%) 33 (84.6%)
Alive/dead Alive 54 (34.4%) 20 (29.4%) 34 (38.2%) 0.251 37 (31.4%) 17 (43.6%) 0.163
Dead 103 (65.6%) 48 (70.6%) 55 (61.8%) 81 (68.6%) 22 (56.4%)
Follow-up (Mo) Mean/SE 5.5/0.3 5.2/0.5 5.7/0.3 0.148 5.4/0.3 5.6/0.5 0.529
Median/min/max 5.2/0.1/15.5 4.9/0.1/15.5 5.5/0.4/14.8 5.2/0.1/15.5 5.7/0.7/12.8
FAK(normal) Mean/SE 0.0/0.0 0.0/0.0 0.1/0.0 0.072 0.0/0.0 0.1/0.1 1.000
Median/min/max 0.0/0.0/2.0 0.0/0.0/0.0 0.0/0.0/2.0 0.0/0.0/1.7 0.0/0.0/2.0
aInformation not reported, not available or not collected.
Dx, diagnosis; FAK (normal), FAK score in normal lung specimen; FAK (tumor), FAK score in tumor specimen; NOS, not otherwise specified; NSCLC, non–small-cell lung 
cancer; Periop Chemo, neoadjuvant and/or adjuvant chemotherapy.
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multivariate analysis, only age at diagnosis (p = 0.02) was 
associated with survival.
DISCUSSION
This study analyzed FAK expression in stage I NSCLC 
and matched normal lung tissues using TMA. Our results 
showed that normal lung tissues did not express FAK, whereas 
high FAK expression can be seen even in stage I cases. This 
finding is important and provides rationale for investigating 
FAK expression in premalignant lesions as a biomarker for 
disease progression into invasive lung cancer. In breast cancer, 
FAK expression can be detected in 66% of preinvasive ductal 
carcinoma in situ lesions and 21% of atypical ductal hyperpla-
sia tissues.15 Whether FAK expression will also be expressed 
in premalignant lesions in the respiratory tract remains to be 
investigated.
One of the earliest investigations suggesting a prog-
nostic role for FAK expression in lung cancer was led by 
Nishimura et al12 who correlated the presence of phosphory-
lated 100 to 130 kDa proteins with regional nodal involvement 
and survival independent of nodal involvement in Japanese 
patients who underwent surgery for NSCLC. Another study 
demonstrated correlation between FAK overexpression and 
more advanced stages of disease using 153 NSCLC frozen 
tissues in Chinese patients.10 The authors reported that FAK 
overexpression was associated with lymph node metastasis 
and more advanced stages of NSCLC. FAK overexpression 
was independently associated with worse overall survival, 
suggesting it as a significant prognostic factor in addition to 
pathologic stage. Another group evaluating FAK expression 
in NSCLC resected from Chinese patients also reported that 
FAK expression was associated with worse prognosis, higher 
incidence of tumor recurrence, and distant metastasis.16 A dif-
ferent retrospective analysis in Chinese patients also revealed 
that FAK expression confers worse survival in surgically 
resected lung adenocarcinoma.17 In comparison, FAK expres-
sion was not a prognostic factor in North American patients 
with small-cell lung cancer, as its expression did not correlate 
with disease stage, recurrence/progression-free survival, or 
overall survival.18
Our study is the first publication to analyze FAK expres-
sion specifically in a large cohort of stage I NSCLC patients 
in North America. In contrast to the aforementioned stud-
ies in NSCLC, we did not detect a correlation between FAK 
expression and survival in our patient population. The survival 
curves that counterintuitively showed a trend of better survival 
in tumors with higher FAK scores (either ≥ 3 or ≥5) may be 
attributed to either random chance or true effect that warrants 
further investigation in this population. Indeed, a recent North 
American study reported in abstract form, analyzing FAK pro-
tein expression by IHC in archival tumors from 216 stage I-III 
NSCLC patients, revealed that FAK IHC score was higher in 
early stage (stage I versus stage II or stage III) tumors, par-
ticularly in adenocarcinomas and in never smokers.19 In the 
adenocarcinoma cases, FAK protein overexpression corre-
lated with better overall survival even after adjusting for stage 
and adjuvant therapy and was significantly higher in tumors 
with epidermal growth factor receptor mutations.
Our study has some limitations. Because the TMA 
approach, there could be heterogeneity in the pattern of FAK 
expression that accounted for these results as well. We also 
did not evaluate normal bronchial epithelium FAK expression 
and activation state which can be increased by exposure to 
cigarette smoke and thus hypothetically may potentially have 
prognostic impact on risk of local recurrences.20 Another limi-
tation is that because phosphorylated FAK cannot be measured 
reliably because of its labile nature and inherent variability in 
formalin-fixed paraffin-embedded specimen processing, we 
measured total FAK in this retrospective study which may 
FIGURE 3.  Overall survival rate and Focal adhesion kinase (FAK) expression in stage I non–small-cell lung cancer patients. 
There is no significant difference between overall survival and FAK expression in lung cancer. Log-rank curve and p values are 
shown for Figure 3A according to FAK score more than or equal to 3 and less than 3 and for Figure 3B according to FAK score 
more than or equal to 5 and less than 5.
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not necessarily indicate an activated pathway. There may also 
be confounding variables found specifically in Asian patients 
that account for the lack of negative prognostic impact of FAK 
in our predominantly Caucasian population. The genomic 
changes found in NSCLC from Asian patients have a different 
profile from those found in patients from Western countries, 
even after controlling for histologic subtype.21 These differ-
ences need to be studied in future investigations of the impact 
of FAK expression and lung cancer prognosis.
Despite the lack of prognostic value of FAK in stage I 
NSCLC, our report provides additional data for other inves-
tigators evaluating the role of FAK in lung carcinogenesis. 
Novel therapeutics to block FAK signaling is in development. 
Further understanding of the impact of modulating FAK in 
various stages of NSCLC will influence the clinical develop-
ment of these agents and the corresponding trial design in 
the future.
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